Search Within

Ellie Rachel Casper

Formats
  1. Meeting Abstract (10)
Groups
  1. Center for Hematologic Malignancies (10)
  2. Department of Medicine (10)
  3. Hematologic Malignancies, Division of (10)
  4. Lymphoma (10)
  5. GME, Medicine (9)
  6. Graduate Medical Education (9)

More Groups

People
  1. Alison Moskowitz (10)
  2. Nivetha Ganesan (10)
  3. Natasha Galasso (9)
  4. Helen Hancock (7)
  5. Robert Stuver (7)
  6. Santosha Vardhana (7)

More People

Years
  1. 2024 (5)
  2. 2023 (4)
  3. 2022 (1)
Publications
  1. Blood (10)
Publishers
  1. American Society of Hematology (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes for patients with classical Hodgkin lymphoma who relapse after autologous stem cell transplant in the era of novel therapies
    Meeting Abstract

    Stuver, R.; Drill, E.; Ganesan, N.; Baron, K.; Casper, E.; Chang, T.; Desai, S. H.; Falade, A. S.; Galasso, N.; Herrera, A. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of peri-transplant radiation on outcomes in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplant
    Meeting Abstract

    Baron, K.; Drill, E.; Ganesan, N.; Merryman, R. W.; Mei, M. G.; Stuver, R.; Desai, S. H.; Falade, A. S.; Iyengar, S.; Micallef, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save